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Abstract
Background: Mosquito stage malaria vaccines are designed to induce an immune response in the
human host that will block the parasite's growth in the mosquito and consequently block
transmission of the parasite. A mosquito membrane-feeding assay (MFA) is used to test
transmission-blocking activity (TBA), but in this technique cannot accommodate many samples. A
clear understanding of the relationship between antibody levels and TBA may allow ELISA
determinations to be used to predict TBA and assist in planning vaccine development.
Methods: Rabbit anti-Pfs25 sera and monkey anti-Pvs25 sera were generated and the antibody
titers were determined by a standardized ELISA. The biological activity of the same sera was tested
by MFA using Plasmodium gametocytes (cultured Plasmodium falciparum or Plasmodium vivax from
malaria patients) and Anopheles mosquitoes.
Results: Anti-Pfs25 and anti-Pvs25 sera showed that ELISA antibody units correlate with the
percent reduction in the oocyst density per mosquito (Spearman Rank correlations: 0.934 and
0.616, respectively), and fit a hyperbolic curve when percent reduction in oocyst density is plotted
against antibody units of the tested sample. Antibody levels also correlated with the number of
mosquitoes that failed to become infected, and this proportion can be calculated from the
reduction in oocyst numbers and the distribution of oocysts per infected mosquito in control
group.
Conclusion: ELISA data may be used as a surrogate for the MFA to evaluate transmission-blocking
vaccine efficacy. This will facilitate the evaluation of transmission-blocking vaccines and
implementation of this malaria control strategy.
Published: 8 August 2007
Malaria Journal 2007, 6:107 doi:10.1186/1475-2875-6-107
Received: 26 January 2007
Accepted: 8 August 2007
This article is available from: http://www.malariajournal.com/content/6/1/107
© 2007 Miura et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Malaria Journal 2007, 6:107 http://www.malariajournal.com/content/6/1/107
Page 2 of 13
(page number not for citation purposes)
Background
The World Health Organization estimates that malaria
causes 300–500 million clinical cases and 1 million
deaths each year worldwide. Parasite strains that are resist-
ant to anti-malarial drugs and mosquito vectors resistant
to insecticides have emerged, enhancing the need for
effective vaccines [1,2]. While multiple stages of the para-
site life cycle are being targeted for vaccine development,
vaccines against mosquito stage antigens are among the
most novel. These mosquito-stage transmission-blocking
(MSTB) vaccines are designed to prevent successful para-
site infection of the mosquito vector and consequently
prevent further parasite spread among humans [3].
In areas of low malaria transmission, MSTB vaccines, as a
component of an integrated programme, may locally
eliminate malaria transmission. Even in areas of high
transmission the entomological inoculation rates (EIR)
correlates with mortality rates, especially in infants [4],
and by reducing transmission rates a MSTB vaccine may
reduce the incidence of disease. A different form of trans-
mission-blocking vaccine, the RTS, S vaccine that blocks
transmission of sporozoites from mosquitoes to humans,
has recently demonstrated significant reduction in both
uncomplicated and severe malaria in trials in Mozam-
bique [5] and similar effects on both transmission and
disease incidence have been widely observed with use of
bed nets [6-8]. In addition, transmission-blocking vac-
cines may prevent the spread of drug-resistant parasites or
parasite mutants that have developed resistance to other
malaria vaccines.
Plasmodium falciparum mosquito stage antigen Pfs25 and
its homologue in Plasmodium vivax, Pvs25, are members of
the P25 family of cysteine-rich 25 kDa antigens. They are
composed of four tandem epidermal growth factor-like
domains and are expressed on zygotes and mature ooki-
nete stages of parasites within mosquitoes [9-11]. Because
P25 is only expressed in the mosquito midgut and not in
the vertebrate host, these proteins have not been under
selection pressure by the host immune system and anti-
genic variation of P25 appears to be more limited than
most vaccine candidates present in pre-erythrocytic and
asexual blood stages [11-13].
An ex vivo assay, the mosquito membrane feeding assay
(MFA), has been used to evaluate vaccines directed against
mosquito stage antigens by measuring the transmission-
blocking activity of the resulting antibody. In this assay, a
mixture of a test serum and malaria gametocytes are fed to
susceptible mosquitoes through a membrane and parasite
oocysts in the mosquito midgut are enumerated approxi-
mately one week later. Using this assay, it has been shown
that monoclonal and polyclonal antibodies, raised in var-
ious animal models, against P25 show transmission-
blocking activity [14-16]. However, previous studies have
not found a consistent relationship between antibody
titer of a serum and transmission-blocking activity in the
MFA. In the case of Pfs25, it is thought that there is a weak
correlation [17], but other reports show there is no corre-
lation between them [18,19]. On the other hand, a con-
sistent relationship between transmission-blocking and
anti-Pvs25 was found in a recent study [20]. Since a Phase
1 human clinical trial with Pvs25 has been conducted in
the U.S. [21] and other trials are anticipated with trans-
mission-blocking vaccines in the future, it is urgent to
establish a method that can be used to evaluate MSTB vac-
cine potential for large numbers of samples coming from
future clinical trials. As antibodies are the principal effec-
tor mechanism for vaccines against P25, it is possible that
other measures of antibody titer such as ELISA might serve
as a surrogate for the MFA.
MFA has been used to assess the transmission-blocking
activity of antibodies directed to other mosquito stage
antigens. There have been several studies that examined
an association of seropositivity to Pfs48/45 or Pfs230 in
human sera from endemic areas with transmission-reduc-
tion in a membrane feed (e.g. [22]). In these studies as
both variables are categorical variables (either positive or
negative) and as the sera may contain multiple specifici-
ties, a detailed continuous relationship between antibody
and blocking cannot be derived. Partly because recom-
binant Pfs48/45 or Pfs230 have not been available, there
have been very few studies looking at more quantitative
aspects. In one study [23] that looked at the correlation
between anti-Pfs48/45 and reduction in oocyst number
by MFA using naturally occurring human sera, a weak but
significant correlation (r2 = 0.24) was found and again it
is possible that the wide scatter in their data reflects other
specificities in the sera. More recently, a monotonic rela-
tionship was shown between the antibody directed to sin-
gle epitope (Epitope I) on Pfs48/45 in mice immunized
with a refolded, recombinant fragment of Pfs48/45 [24].
However, there are still no reported studies on well char-
acterized, total anti-Pfs48/45 activity and the quantitative
effect on reduction in oocyst numbers.
Different endpoints for the MFA have been used for meas-
uring transmission-blocking activity: a reduction in the
oocyst density per mosquito or an increase in the propor-
tion of mosquitoes that have no parasites. The former is
generally used for laboratory studies, but it is the latter
that is thought to best predict the likely efficacy of vac-
cines under field conditions. Since it is much easier to
measure antibody by ELISA than to measure either a
reduction in oocyst density or the decrease in malaria
transmission in the field, it would be useful to understand
the link between antibody titer and these two measures of
transmission-blocking to facilitate vaccine development.Malaria Journal 2007, 6:107 http://www.malariajournal.com/content/6/1/107
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In addition to the absolute level of the antibody, it is pos-
sible that the transmission-blocking activity may depend
on the "quality" of the antibody, e.g., different fine specif-
icities or antibody affinities resulting from maturation of
the antibody response, either as a result of boosting or as
a result of the use of different adjuvants. However, it is not
clear whether adjuvant selection changes only the amount
of antibody induced by the vaccine, or whether it also
changes the quality of the antibody with respect to trans-
mission-blocking activity.
In this paper, sources of error in measuring transmission-
blocking activity were examined by evaluating the activity
of sera raised in rabbits and rhesus monkey against yeast-
produced Pfs25 and Pvs25, both purified to standards of
clinical grade material, formulated with several adjuvants.
The reduction in oocyst density and the proportion of
infected mosquitoes can be directly related to the anti-P25
antibody titer in the membrane feed. For the conditions
tested, different adjuvants, time after immunization or the
species of animal immunized result in antibody with sim-
ilar specific transmission-blocking activity.
Methods
Antigen preparation
Clinical grade Pfs25 was prepared as described [25]. In
brief, the Pfs25 sequence from Lys-23 to Thr-193 was sub-
cloned into the pPIC9K vector and transformed into
Pichia pastoris. After fermentation, a series of chromatogra-
phy steps was used for purification and buffer exchange as
follows: Nickel nitrilotriacetic acid Superflow column,
Phenyl Sepharose hydrophobic interaction chromatogra-
phy and Superdex 75 size-exclusion column.
Clinical grade Pvs25 was prepared as described [26] In
brief, the parasite gene encoding Pvs25 was subcloned
into the plasmid YEpRPEU-3 and transformed into Sac-
charomyces cerevisiae VK1 cells. After fermentation, a series
of chromatography steps was used for purification and
buffer exchange as follows: Nickel nitrilotriacetic acid
Superflow column, Phenyl Sepharose hydrophobic inter-
action chromatography and Superdex 75 size-exclusion
column.
Characterization of these two products has been previ-
ously reported [25,26].
Rabbit immunization
All rabbit studies were carried out with antisera obtained
from New Zealand White rabbits (Spring Valley Laborato-
ries, Frederick, MD). Four rabbits were immunized by
intramuscular injection with 0.5 ml of saline containing
80 µg of Pfs25 adsorbed onto 800 µg of alum (Alhydro-
gel®-aluminum hydroxide; HCI Biosector, Frederikssund,
Denmark) and another 4 rabbits were immunized with 80
µg of Pfs25 formulated with Montanide ISA720 (SEPPIC,
Paris, France). Animals were immunized on days 0, 28
and 56, and bled on days 0 (before immunization), 28
(before boost), 42 and 70.
Rhesus monkey immunization
This animal study was done in compliance with National
Institutes of Health (NIH) guidelines and under the aus-
pices of an Animal Care and Use Committee-approved
protocol. Ten monkeys (Macaca mulatta, six male and four
female) were randomly divided into two groups. The two
groups of five animals each received: (a) 15 µg of Pvs25
adsorbed onto 600 µg of alum, or (b) 15 µg of Pvs25
adsorbed onto 600 µg of alum and 250 µg of CpG 10105
(Coley Pharmaceutical Group, Wellesley, MA). CpG
10105 has the sequence TCG TCG TTT TGT CGT TTT TTT
CGA using a fully phosphorothioate backbone. The mon-
keys were immunized on days 0, 28 and 181 and bled on
days 0 (before immunization), 42, 90 and 195.
ELISA
Flat-bottom 96-well ELISA plates (Immunolon 4; Dynex
Technology Inc., Chantilly, VA) were coated with 100 ng/
well of Pfs25 or Pvs25 at 4°C overnight. The plates were
blocked with 5% skim milk (Difco, Detroit, MI) in Tris
Buffered Saline (TBS) (BioFluids, Camarillo, CA) for two
hours at room temperature. Animal sera were diluted in
buffer that contained 0.1% BSA (Sigma Chemical Co., St.
Louis, MO) and 0.05% Tween 20 (Sigma Chemical Co.)
in TBS. Diluted sera were added to antigen-coated wells in
triplicate and incubated for two hours at room tempera-
ture. After extensive washing with 0.1% Tween 20 in TBS,
the plates were incubated with the secondary antibody
conjugated with alkaline phosphatase (Kirkegaard & Perry
Laboratories, Inc., Gaithersburg, MD) for two hours at
room temperature. Bound antibodies were visualized by
adding the substrate solution (p-nitrophenyl phosphate
Sigma 104 substrate; Sigma Chemical Co). The absorb-
ance at 405 nm was read using a SPECTRAmax 340 PC
microplate reader (Molecular Devices Co., Sunnyvale,
CA).
Standardization of the ELISA was accomplished by com-
parison with a standard antiserum tested on each ELISA
plate. Three standard sera (anti-Pfs25 serum from mice
immunized with Pfs25 formulated with Montanide
ISA720, anti-Pfs25 rabbit serum and anti-Pvs25 rhesus
monkey serum) were prepared using sera obtained two
weeks after the 2nd immunization, aliquoted, and stored
at -80°C until required. Serially diluted standard sera were
tested and assigned unit values as the reciprocal of the
dilution giving an O.D. 405 = 1 in the ELISA. In each test
ELISA plate, serially diluted standard sera were applied to
prepare a standard curve. Using the standard curve, the
absorbance of individual test sera was converted to anti-Malaria Journal 2007, 6:107 http://www.malariajournal.com/content/6/1/107
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body units (SOFTmax PRO ver.3; Molecular Devices Co.,
Sunnyvale, CA).
MFA with monoclonal antibody 4B7
Anti-Pfs25 monoclonal antibody 4B7 (MAb 4B7) was
assayed as described previously [18]. Briefly, the antibody
was serially diluted from 1:24 to 1:384 with pooled heat
inactivated human O serum, which was made from indi-
viduals who have not been previously exposed to malaria,
then mixed with mature in vitro cultured P. falciparum
gametocytes (NF54 isolate) and fed to Anopheles stephensi
mosquitoes through a membrane-feeding apparatus.
Mosquitoes were kept for 8 to 10 days after feeding to
allow parasites to develop into mature oocysts. Infectivity
was measured by dissecting at least 20 mosquitoes per
sample, staining with Mercurochrome, and counting the
number of oocysts per midgut. Within one membrane
feeding experiment (i.e. a set of membrane feeds done on
one day with a single shared control feed) each concentra-
tion of MAb 4B7 was tested in a single membrane feeder.
The membrane feeding experiment was repeated twice on
different days at four different concentrations.
The percent inhibition of oocyst density per mosquito was
determined by the formula: 100 - (arithmetic mean of
oocysts in the test sample/arithmetic mean of oocysts in
pooled human O serum) × 100.
The anti-Pfs25 antibody units used in the membrane feed-
ing apparatus for each dilution of MAb 4B7 were calcu-
lated based on the ELISA-determined antibody units of
the original MAb and the dilution factor of the feeding
sample.
MFA with rabbit sera
Anti-Pfs25 rabbit sera were tested with cultured P. falci-
parum gametocytes in a similar fashion to the MAb 4B7.
Six pooled sera were made from: 1) Day 0 sera of 4 rabbits
immunized with Pfs25 and alum (alum group), 2) Day 0
sera of 4 rabbits immunized with Pfs25 and ISA720 (ISA
group), 3) Day 42 sera of alum group, 4) Day 42 sera of
ISA group, 5) Day 70 sera of alum group, 6) Day 70 sera
of ISA group. The pooled sera and individual rabbit sera
were heat inactivated, diluted with the pooled heat inacti-
vated human O serum at 1:2 and 1:8 dilutions, then
mixed with the P. falciparum gametocytes and fed to mos-
quitoes as above. In each membrane feeding experiment,
the pooled or individual sera were tested in a single mem-
brane feeding apparatus at 1:2 and 1:8 dilution. A limited
set of the sera were retested on three occasions.
Percent inhibition of oocyst density per mosquito was
determined by the formula: 100 - (arithmetic mean of
oocysts in the test sample/arithmetic mean of oocysts in
pooled day 0 serum for that particular adjuvant) × 100.
Percent inhibition of infected mosquitoes was determined
by the formula: 100 - (percent of infected mosquitoes in
the test sample/percent infected mosquitoes in pooled
day 0 serum for that particular adjuvant) × 100.
As for the MAb 4B7, the anti-Pfs25 antibody units in each
membrane feeding test sample were calculated based on
the ELISA-determined antibody units in the original
serum and the dilution factor of the feeding sample.
MFA with P. vivax in Thailand
Anti-Pvs25 rhesus monkey sera were tested for transmis-
sion-blocking activity with P. vivax infected human blood
as a source of gametocytes. Informed consent was
obtained from all volunteers. Volunteers came to malaria
clinics in north-west Thailand and were diagnosed with P.
vivax  infection microscopically. Blood was collected in
heparin. Less than two hours after collection, blood was
centrifuged and the plasma was removed. Mixtures of
packed erythrocytes and heat inactivated test sera, which
were diluted with a pool of heat inactivated American nor-
mal human AB+ serum (prepared from malaria-naïve
donors) as 1:2 or 1:8 dilutions, were made. Mixtures were
immediately placed in feeding apparatuses and offered to
Anopheles dirus. These mosquitoes were individually sepa-
rated to remove unfed mosquitoes and incubated at 28°C
for seven to nine days before dissection of mosquito mid-
guts. The oocysts formed in the midgut were examined
and counted by microscopy. The pooled normal heat
inactivated human AB serum was used as an indicator of
a successful feed for each set of rhesus sera and for each
parasite source. If the arithmetic mean of oocyst numbers
for the human AB sera was less than four in 20 to 40 dis-
sected mosquitoes, the feeding result was discarded. Each
sample was tested with parasites from different patients,
until at least three successful feeds were achieved. Only
data sets which showed an arithmetic mean number of
oocysts for the day 0 serum (both 1:2 and 1:8 dilutions)
over four, were used to calculate the transmission-block-
ing activity for each test serum.
Percent inhibition of oocyst density per mosquito was
determined by the formula: 100 - (arithmetic mean of
oocysts in the test for a particular monkey/arithmetic
mean of oocysts in the day 0 serum for that same monkey
and for that particular dilution) × 100.
Anti-Pvs25 antibody units of a feeding sample were calcu-
lated based on the ELISA-determined antibody units in
the original serum and the dilution factor of the feeding
sample.
Statistics
For comparing antibody units of two groups, the Mann-
Whitney U-test was performed. To test the correlationMalaria Journal 2007, 6:107 http://www.malariajournal.com/content/6/1/107
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between units of antibody and transmission-blocking
activity, a Spearman rank correlation was used. Statistical
analyses were done by UNISTAT 5.0 (P-STAT Inc.,
Hopewell, NJ). Probability values less than 0.05 are con-
sidered as significant. Curve fitting analyses were per-
formed using Sigma Plot (SPSS Inc., Chicago, IL) and the
regression analysis used to calculate the concentration of
antibody giving 50% inhibition of oocyst numbers (Ab50)
and its 95% confidence limit. Note that this Ab50 value is
calculated from the whole data and its use is analogous to
the use of IC50 values for drug studies. The antibody
required to give 80% inhibition was also calculated from
the fitted regression analysis as a value indicating a level
of antibody that could be expected to have a biological
impact.
Computer simulations model of the MFA
Two computer simulations models were written to evalu-
ate sources of experimental errors in correlating antibody
levels with the percent inhibition of oocyst density per
mosquito and to examine the relationship between reduc-
tion in oocyst numbers and the proportion of mosquitoes
with no infection. Data sets were assembled from experi-
mental data on the oocyst density in individual mosqui-
toes measured in control feeds (i.e., mosquitoes feeding
on gametocytes but with no added antibody). Two P. fal-
ciparum data sets were obtained from the two experiments
to measure MFA activity in rabbit anti-Pfs25 sera
described above. Data sets were also obtained from con-
trol feeds using P. vivax blood from volunteers. These data
were obtained during the experiments to measure trans-
mission-blocking activity with rhesus anti-Pvs25 sera.
Details of the data sets are listed in Table 1. Both sets of P.
falciparum data had similar mean oocyst numbers. How-
ever, the computer simulation picks values for the entire
range (0 to 131) oocysts per mosquito, so a much larger
range is sampled than indicated from these mean values.
Similarly, the P. vivax data cover a range of 0 to 605
oocysts per mosquito.
The first programme was used to test the relationship
between reduction in average oocyst numbers and reduc-
tion in the proportion of mosquitoes infected. Specifically
it tested if the proportion of infected mosquitoes in a test
feed can be predicted from the measured survival in indi-
vidual feeds and the observed distribution of oocyst den-
sities in control feeds. It assumes that the survival of each
oocyst is independent of the distribution of oocysts in the
mosquito population, i.e., it assumes that an antibody
that gives a 50% reduction in oocyst density in a mosquito
population with an average oocyst density of for example
6.6 per mosquito will also give a 50% reduction if the con-
trol mosquitoes have an average of 230 per mosquito. For
each datum point in the simulation, the programme used
the number of mosquitoes dissected in an actual control
feed (nc), the number of test mosquitoes dissected (nt)
and the observed oocyst density in each test feed. The ratio
of experimentally determined oocyst densities in test to
control feeds was used as a measure of the probability of
oocyst survival (ps) in the presence of antibody. In exper-
imental feeds where the number of oocysts in the test
feeds was greater than in control, ps was set to 1.0. The
programme randomly selected nc mosquitoes as the sim-
ulated control and nt mosquitoes as the simulated test
group from the appropriate data set. For each of the mos-
quitoes in the test group, the simulated number of oocysts
was calculated using a binomially distributed random
number, with probability ps, then the % infected mosqui-
toes in the test group was calculated. The simulation was
run for each of the experimental feeds using P. falciparum
blood in the presence of rabbit anti-Pfs25 and for each
feed using P. vivax infected blood in the presence of Rhe-
sus anti-Pvs25. The simulation was repeated 40 times for
each experimental data point.
The second programme was used to simulate the relation-
ship between antibody concentration and % inhibition of
oocyst numbers. The programme was identical, except
that the probability of survival, ps, used for each simula-
tion was calculated from the experimentally determined
hyperbolic best fit correlating % inhibition of oocyst den-
sity with antibody concentration.
Results
Anti-Pfs25 monoclonal antibody 4B7 has potent 
transmission-blocking activity
To study the relationship between antibody concentration
and transmission-blocking activity for P. falciparum, the
Table 1: Experimental data sets used for simulation studies
Data Set No. Mos.a Mean Ooc.b C.V.c % Uninf.d
Rabbit anti-Pfs25
Pf1 81 28.05 1.00 7
Pf2 94 28.99 0.63 0
Rhesus anti-Pvs25
Pv1 140 6.66 1.10 34
Pv2 160 8.56 0.95 23
Pv3 146 13.50 1.15 33
Pv4 168 17.14 0.90 14
Pv5 140 22.56 0.90 21
Pv6 160 34.21 0.92 19
Pv7 155 56.18 0.99 22
Pv8 175 93.89 0.96 25
Pv9 178 135.35 0.96 28
Pv10 119 231.10 0.65 11
a Number of dissected mosquitoes.
b Mean number of oocysts per mosquito.
c Coefficient of variation in mean.
d Percent of uninfected mosquitoes.Malaria Journal 2007, 6:107 http://www.malariajournal.com/content/6/1/107
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relationship between the transmission-blocking activity
of a monoclonal antibody and its concentration deter-
mined by ELISA was investigated. Anti-Pfs25 monoclonal
antibody 4B7 (MAb 4B7) has been previously described
by Kaslow and colleagues as being directed to Pfs25 and
having transmission-blocking activity in MFA [14]. The
MAb 4B7 was serially diluted and the samples were used
in MFA. As shown in Figure 1 for one of the three feeding
experiments, MAb 4B7 showed concentration-dependent
transmission-blocking activity; a plot of % inhibition of
oocyst density per mosquito versus antibody concentra-
tion determined by ELISA followed a hyperbolic curve (r2
= 0.945): % inhibition = 100-100/(1+4.69 × 10-5 × ELISA
units)13.8. This curve gives a 50% inhibition at 1038 units
(95% CI range 677 to 1562). The other two feeding exper-
iments gave similar good fits (r2 = 0.967 and 0.903). They
used a narrower range of antibody concentrations (four 2-
fold dilutions each instead of five) and gave Ab50 of 477
(312 to 720) and 897 (335 to 2169), respectively. Note
that the confidence intervals reflect intra-assay variation
only. Errors in the determination of the number of oocysts
in the control group will cause a systematic error in all of
the calculated % errors within one experiment and will
have a small impact on the fit within one experiment but
they will contribute to the inter-assay variation.
Pfs25 induced transmission-blocking antibody in rabbits
To extend these results to polyclonal antisera and to
another species, groups of four rabbits were immunized at
day 0 and 28 with either Pfs25 adsorbed onto alum
(Pfs25-alum group) or Pfs25 formulated with Montanide
ISA720 (Pfs25-ISA group). Day 0 sera from both groups
showed negligible anti-Pfs25 antibody measured by
ELISA (Figure 2). Two weeks (day 42) after the second
immunization, all animals made significant levels of anti-
Pfs25 antibodies. The two different groups showed geo-
metric means (GM) of 5,831 units for the Pfs25-alum
group and 43,983 units for the Pfs25-ISA group. Differ-
ences between the two groups in ELISA titer do not reach
statistical significance (Mann-Whitney U-test, p = 0.057).
On day 70, the GM of the Pfs25-ISA group was 144,973
and that of Pfs25-alum group was 14,202, and at this time
point the antibody units of the Pfs25-ISA group are signif-
icantly higher than those of the Pfs25-alum group (Mann-
Whitney U-test, p < 0.0001).
The biological activities of individual and pooled rabbit
sera were then tested with mature in vitro-cultured P. fal-
ciparum gametocytes by MFA. As shown in Figure 3, there
is a strong correlation between the antibody ELISA units
and % inhibition of oocyst density per mosquito; the
Spearman Rank Correlation (rs) is 0.934 (95% CI: 0.878–
0.965, p < 0.0001). The relationship followed a hyper-
bolic curve (r2 = 0.697): % inhibition = 100-100/(1+6.24
× 10-4 × ELISA units)1.59 giving 50% inhibition at 877
Kinetics of induction of rabbit anti-Pfs25 antibody Figure 2
Kinetics of induction of rabbit anti-Pfs25 antibody. 
Groups of 4 rabbits were immunized with (i) 80 µg of Pfs25 
adsorbed onto alum (blank bars), or (ii) 80 µg of Pfs25 for-
mulated with Montanide ISA720 (hatched bars). Animals 
were immunized on days 0, 28 and 56, and bled on days 0, 
28, 42 and 70. Sera were tested for anti-Pfs25 antibody con-
centration by ELISA relative to a standard rabbit anti-Pfs25 
serum which has 100,000 units. ELISA values of individual 
rabbits are plotted and the geometric mean ± SE for the 
group are also shown. On day 70, the antibody units of the 
Pfs25-ISA group are significantly higher than those of the 
Pfs25-alum group (Mann-Whitney U-test, p < 0.0001).
Concentration-dependent TB activity of anti-Pfs25 mono- clonal antibody 4B7 Figure 1
Concentration-dependent TB activity of anti-Pfs25 
monoclonal antibody 4B7. MAb 4B7 was serially diluted 
with pooled human O serum to give the antibody concentra-
tion in the feed as indicated (X-axis), mixed with mature in 
vitro-cultured P. falciparum gametocytes and fed to A. 
stephensi mosquitoes. Approximately one week later, oocysts 
were counted and % inhibition of oocyst density per mos-
quito relative to mosquitoes fed with a pooled human O 
serum is plotted (Y-axis). Line represents regression of result 
by use of a hyperbolic equation.
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units (CI 629 to 1212) based on two membrane feeding
experiments each with one control feed and 20 test feeds
(n = 40) Based on this hyperbolic curve, 80% inhibitions
of oocyst density per mosquito were achieved with
approximately 2,800 antibody ELISA units. A limited set
of the sera were tested on three other occasions giving
Ab50 of 594 (CI 428 to 816, r2 = 0.782, n = 11, one mem-
brane feeding experiment); 2100 (CI 1009 to 3969, r2 =
0.663, n = 14, two membrane feeding experiments with
eight and six test feeds, respectively).
Transmission-blocking activity in MFA can also be evalu-
ated by determining the proportion of infected mosqui-
toes. The relationship between the antibody ELISA units
and % inhibition of infected mosquitoes was also strong
(rs = 0.900, 95% CI: 0.818–0.946, p < 0.0001), and the
relationship followed a hyperbolic curve (r2 = 0.858): %
inhibition = 100-100/(1+1.29 × 10-6 × ELISA units)97.5.
However, the % inhibition of infected mosquitoes was
less than the % inhibition of oocyst density per mosquito
when tested at the same antibody concentration.
As part of this study, the impact of the selection of adju-
vant or the number of immunizations on the inhibitory
activity of the sera was also examined. Regardless of the
adjuvant utilized (Figure 4a), or the number of days after
immunization (Figure 4b), all data points followed the
same hyperbolic curve when the % inhibition of oocyst
density per mosquito was plotted against antibody units.
Pvs25 induced transmission-blocking antibodies in rhesus 
monkeys
These results were extended to P. vivax. Five rhesus mon-
keys (Macaca mulatta) were immunized with the vivax
homologue of Pfs25, i.e., clinical grade Pvs25 adsorbed
onto alum (Pvs25-alum group). A second group of 5
monkeys was immunized with Pvs25 adsorbed onto alum
with the addition of CpG10105 (Pvs25-CpG group). As
shown in Figure 5, there was a negligible concentration of
specific antibodies in the monkey sera before immuniza-
tion (day 0), but by two weeks (day 42) after the second
immunization, Pvs25 elicited significantly higher anti-
body titers for both the Pvs25-alum group (GM was 3,436
units) and the Pvs25-CpG group (12,351 units). By day
90, the antibody units had declined in both groups (GM
of the Pvs25-alum group was 589 and the Pvs25-CpG
group was 1,738). Two weeks (day 195) after a third
immunization, the antibody values exceeded the day 42
antisera (GM of the Pvs25-alum group was 12,044 and
Effect of adjuvant selection and time after immunization on  TB activity Figure 4
Effect of adjuvant selection and time after immuniza-
tion on TB activity. Individual and pooled rabbit anti-Pfs25 
sera were diluted 1:2 and 1:8, and then tested for TB activity 
in mosquito membrane feeding assays as described in the leg-
end to Figure 3. (a) data were categorized according to the 
adjuvant used for immunization (open circles: alum; closed 
circles: Montanide ISA720) while in (b) data were categorized 
according to number of days after initial immunization (open 
triangles: day 42; closed triangles: day 70). Lines represent 
regression of result by use of a hyperbolic equation. Four 
data points, which showed more than 30,000 antibody units 
and 100% inhibition of oocyst density per mosquito, are not 
shown in these figures.
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Correlation of TB activity and antibody units of rabbit anti- Pfs25 sera Figure 3
Correlation of TB activity and antibody units of rab-
bit anti-Pfs25 sera. Groups of 4 rabbits were immunized 
with 80 µg of Pfs25 as described in the legend to Figure 2. 
Individual and pooled sera were diluted 1:2 and 1:8, and then 
tested for TB activity in mosquito membrane feeding assays 
using sexual stages of P. falciparum and A. stephensi mosqui-
toes. Anti-Pfs25 antibody units of each sample prior to dilu-
tion were determined by ELISA. Antibody unit values for the 
diluted sera are plotted on the X-axis and % inhibition of 
oocyst density per mosquito (open triangles) of the same 
sample or % inhibition of infected mosquitoes (closed circles) 
of the same sample is plotted on the Y-axis. There is a strong 
correlation between the antibody units and % inhibition of 
oocyst density per mosquito or % inhibition of infected mos-
quitoes (the Spearman Rank Correlations are 0.934 and 
0.900, respectively). Lines represent regression of result by 
use of a hyperbolic equation: Solid line – correlation between 
antibody units and % inhibition of oocyst density per mos-
quito; broken line – correlation between antibody units and 
% inhibition of infected mosquitoes.
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the Pvs25-CpG group was 20,392). The GM of the Pvs25-
CpG group was higher than that of the Pvs25-alum group
on all days after immunization, but there were no statisti-
cally significant differences using a Mann-Whitney U-test.
Figure 6 shows the MFA results with these monkey sera
and the relationship with antibody titer as determined by
ELISA. As in the case of the data obtained with rabbit anti-
Pfs25 sera, it is apparent that there is a significant correla-
tion between antibody ELISA units and % inhibition of
oocyst density per mosquito in rhesus monkey sera (rs =
0.616, 95%CI: 0.429–0.752, p < 0.0001). Moreover, the
data points followed a hyperbolic curve (r2 = 0.249): %
inhibition = 100 × ELISA units/(1567 + ELISA units) when
the % inhibition of oocyst density per mosquito was plot-
ted against antibody units. Based on the fitted hyperbolic
curve, 50 and 80% inhibitions were achieved with
approximately 1,500 and 6,000 antibody units, respec-
tively.
Computer simulation of MFA
For both P. falciparum and P. vivax, the computer simula-
tions based on the reduction in oocyst density gave a good
fit between the predicted and experimentally measured
proportion of mosquitoes infected (Figure 7). For P. falci-
parum, the Spearman rank correlation, rs was 0.937 for the
correlation of mean % infected mosquitoes from simu-
lated data with the experimental data and 0.967 for the
correlation of mean % infected from simulated and a sin-
gle simulated data set. This suggests that the model not
only gave the expected relationship but also closely pre-
dicted the variance in the experimental data. For P. vivax
the fit was not as good with rs values of 0.465 and 0.675,
respectively, and the simulated average % infected mos-
quitoes vs. experimental % infected deviated from the
expected linear relationship at high % infected.
In the simulation of oocyst density as a function of anti-
body concentration, the computer simulations showed
that the expected errors from sampling were substantially
Correlation of TB activity with antibody titer using anti-Pfs25  sera from rabbits and anti-Pvs25 sera from rhesus monkeys Figure 6
Correlation of TB activity with antibody titer using 
anti-Pfs25 sera from rabbits and anti-Pvs25 sera from 
rhesus monkeys. Rabbits were immunized with Pfs25 and 
the antisera were tested in mosquito membrane feeding 
assays with P. falciparum parasites and A. stephensi mosquitoes 
as described in legend to Figure 3. Rhesus monkeys were 
immunized with Pvs25 as described in legend to Figure 5 and 
the antiserum was diluted with a pool of normal human AB+ 
serum as 1:2 or 1:8 dilutions. The diluted monkey sera were 
tested in membrane feeding assays using parasites derived 
from vivax-infected patients in Thailand and A. dirus mosqui-
toes. Antibody units in the sera were determined by stand-
ardized ELISA. (a): Rabbit data (open circles) and individual 
monkey data (closed circles) are shown. There is a significant 
correlation between antibody units and % inhibition of 
oocyst density per mosquito in rabbit and in monkey sera 
(the Spearman Rank Correlations are 0.934 and 0.616, 
respectively). Lines represent regression of monkey result by 
use of a hyperbolic equation. Four points of rabbit data, 
which showed more than 30,000 antibody units and 100% 
inhibition of oocysts, are not shown in this figure. (b):The val-
ues of the test sera were grouped as shown. Average per-
cent oocyst inhibition for rabbit sera (blank bars) or monkey 
sera (hatched bars) in each ELISA range + SD are shown.
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Kinetics of antibody response to immunization with Pvs25 in  rhesus monkeys Figure 5
Kinetics of antibody response to immunization with 
Pvs25 in rhesus monkeys. Groups of 5 monkeys were 
immunized with (i) 15 µg of Pvs25 adsorbed onto 600 µg of 
alum (blank bars), or (ii) 15 µg of Pvs25 adsorbed onto 600 
µg of alum and 250 µg of CpG 10105 (hatched bars). Animals 
were immunized on days 0, 28 and 181, and bled on days 0, 
42, 90 and 195. All sera were tested by ELISA and compared 
to a standard rhesus anti-Pvs25 serum which has 20,000 
units. ELISA values of individual monkeys are plotted and the 
geometric mean ± SE for the group are also shown.Malaria Journal 2007, 6:107 http://www.malariajournal.com/content/6/1/107
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lower than the observed fit (Figure 8). The r2 for P. falci-
parum hyperbolic fit was 0.697 for experimental data and
the mean r2 for the simulated data was 0.899. For P. vivax,
the respective values were 0.249 and 0.633.
Discussion
This is the first study that clearly shows that the biological
activity of transmission-blocking antisera is a direct func-
tion of antibody titer. There are two reasons that can be
suggested to account for the correlation observed in this
study. One reason may be the way that the MFA were per-
formed, particularly with respect to the number of mos-
quitoes analysed and the number of samples that were
used. The second reason may be the precision with which
the antibody titers were determined in a standardized
ELISA format.
For transmission-blocking immunity measured as a
decrease in the oocyst density per mosquito, a reproduci-
ble hyperbolic relationship between antibody concentra-
tion measured by ELISA and the level of inhibition was
observed. Part of this evaluation tested if antibody con-
centration alone was the major determinant of transmis-
sion-blocking activity or whether other characteristics of
antibodies might also affect the biological activity of the
sera. To address this question, the selection of adjuvant
and the time the sera was collected after immunization
was assessed to see the impact on ELISA units and trans-
mission-blocking activity tested by MFA. Aluminum salts
(alum) are commonly used in vaccines in clinical use
although it is a relatively weak adjuvant for antibody
induction in humans [27,28]; such formulations have
been reported to give primarily a Th2 response in mice
[29]. Montanide ISA720, a water-in-oil emulsion adju-
vant, has been used with malarial vaccine candidates both
in animal studies [30-34] and in human trials [35-37].
Unmethylated CpG dinucleotides, which are found fre-
quently in genomes of bacteria and viruses, trigger an
innate immune response [38] and also stimulate B cell
proliferation and immunoglobulin secretion [39]. Oligo-
nucleotides containing CpG motifs have been shown to
be strong adjuvants for DNA- or protein-based immuno-
gens [40-43] and have been used for human trials [44,45];
they elicit primarily a Th1 response in mice [40,46].
In the case of rabbits immunized with Pfs25, adjuvant
selection and the additional times of immunization sig-
nificantly changed the quantity of antibody produced
(Figure 2), but did not change the quality of the antibody
with respect to transmission-blocking activity when nor-
malized for antibody concentration (Figure 4). The data
clearly shows that regardless of adjuvant or time after
immunization, all transmission-blocking data followed
the same hyperbolic curve, indicating that antibody titer
was the major determinant of biological activity. In the
case of rhesus monkeys immunized with Pvs25, no statis-
tically significant differences in ELISA values between the
Pvs25-alum group and the Pvs25-CpG group could be
detected at any time point (Figure 5). Although the GM of
antibody units of the Pvs25-CpG group were always
higher than those of the Pvs25-alum group on all days,
including days 14, 28, 175, 223, 269 and 365 (data not
shown), the small group sizes preclude a definitive test of
significance using the non-parametric Mann-Whitney U-
test. Like the rabbit data, the MFA data of monkeys
showed that neither adjuvant selection nor time of sera
collection changed the transmission-blocking activity
when it was normalized for antibody concentration (data
not shown). Based on these results, a vaccine formulation
Comparison of predicted and measured oocyst density per  mosquitoes Figure 8
Comparison of predicted and measured oocyst den-
sity per mosquitoes. Experimental data (open circles) are 
shown for anti-Pfs25 (a) and anti-Pvs25 (b) and are the same 
feeds shown in Figure 4 and Figure 6, respectively. A single 
simulated data set (closed circles) is shown for each.
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Comparison of predicted and measured percentage of  infected mosquitoes Figure 7
Comparison of predicted and measured percentage 
of infected mosquitoes. Predicted values are the average 
of 40 computer simulations per point for membrane feeds 
based on the experimental feeds measuring TB activity of 
rabbit anti-Pfs25 sera (a) and rhesus anti-Pvs25 sera (b). 
These are the same feeds shown in Figure 4 and Figure 6, 
respectively.
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that shows the highest immunogenicity judged by ELISA
should be selected for a human anti-P25 vaccine, assum-
ing that there are no safety concerns.
Surprisingly, regardless of the parasite antigen (Pfs25 or
Pvs25) or the species producing the antibodies (rabbit or
monkey) or the species of mosquito (A. stephensi or A.
dirus) used in the MFA, similar transmission-blocking
activity was obtained when the % inhibition of oocyst
density per mosquito was plotted against antibody ELISA
units (Figure 6a). In addition, the anti-Pfs25 monoclonal
antibody 4B7, produced by a murine hybridoma, also dis-
played the same hyperbolic curve as the rabbit anti-Pfs25
sera (Figures 1 and 6). Approximately 1,000 (for anti-
Pfs25) or 1,500 (for anti-Pvs25) units of antibody gives
50% inhibition of oocyst density per mosquito and 80%
inhibition can be achieved with approximately 3,000 (for
anti-Pfs25) or 6,000 (for anti-Pvs25) antibody units.
Since the data with P. vivax were scattered, it is not possi-
ble to judge whether anti-Pfs25 sera had really higher
transmission-blocking potency than that of anti-Pvs25
sera. Overall, these data were surprisingly close consider-
ing the many inherent variables in this biological assay
and the many differences intrinsic to the two assay sys-
tems. The important point of these studies is the support
for the hypothesis that the same quantity of antibody will
be required to achieve a desired level of transmission-
blocking activity in human clinical trials with P25.
The reduction in the number of mosquitoes also had a
simple relationship with antibody. However, as mosqui-
toes usually had many oocysts, the concentration of anti-
body required to give a 50% reduction in the number of
infected mosquitoes was much higher than the amount
required to kill 50% of the oocysts. Again as expected,
from the need to kill multiple oocysts, the shape of the
relationship was also different: where as the curve for per-
cent killing was close to a simple rectangular hyperbola
(exponent of 1.57 in the two parameter fit compared to
1.0 for a simple rectangular hyperbola), the relationship
between antibody and % uninfected mosquitoes was
much steeper (exponent 97.5) consistent with the need to
independently kill multiple oocysts.
Because the MFA is a complex, time and labor-consuming
assay, most of the MSTB vaccine studies have used 30 or
fewer mosquitoes per sample [14-16,18,19,47]. However,
transmission-blocking activity determined from small
numbers of mosquitoes per feed are likely to lead to large
sampling errors, because the distribution of oocysts per
mosquito is highly over dispersed (Table 1). With the
MFA reported in this paper for P. falciparum, the average
oocyst density per mosquito was similar for each of the
control feeds. However, this is unusual. In general, wide
variations could be expected from one experiment to
another. Actually, in infections resulting from mosquitoes
directly feeding on infected humans, large variations in
oocyst numbers have also been reported [48]. This was
particularly the case for the P. vivax feeds. Approximately
half of the feeds had less than 4 oocysts per mosquito
(these were not analysed), and the remainder varied from
an average of 6.6 to 230. Since P. vivax cannot be cultured
continuously and the only source of the gametocytes is
infected non-human primates or humans, it is difficult to
control the quality of parasites for the assay. Therefore, the
MFA data obtained with P. vivax were more scattered than
the data tested with culture-derived P. falciparum gameto-
cytes (Figure 6). Presumably in these cases, in which zero
or few oocysts per mosquito were observed, the gameto-
cytes were in insufficient quantity or inappropriate state of
maturation to give a productive mosquito infection.
Because of the dispersion, Medley et al suggested that less
than 100 mosquitoes per feed, especially less than 50 per
feed, provide unreliable estimates of transmission-block-
ing activity [49]. An estimate of the contribution of this
over dispersed distribution can be obtained from the
computer simulations of MFA. For the simulation models,
the oocyst distributions in control mosquitoes and the
numbers of mosquitoes dissected in control and test
groups were used to obtain the experimental data. Thus
the scatter in the simulated data only includes variation
due to sampling. However, these simulations based on
actual control feeds, showed that even with 20 mosqui-
toes per feed, the variation due to the sampling error is
small compared to other as yet other unidentified varia-
tions between replicate feeds (Figure 8). This is similar to
the results recently reported from another study of oocyst
distributions obtained from membrane feed data using
cultured  P. falciparum gametocytes [50]. These results
show that reliable estimates of transmission-blocking
activity require multiple feeds per sample with relatively
small numbers of mosquitoes rather than a single feed
with large numbers of mosquitoes. In this paper, each rhe-
sus serum was tested with P. vivax from at least three dif-
ferent patients. When the average % inhibition was
calculated as described in Materials and Methods, there
was a significant correlation between antibody titer and
the transmission-blocking activity.
Depending on the underlying biological relationship
between antibody level and killing of parasites, one may
expect that for a given antibody level, the proportion of
mosquitoes that are prevented from becoming infected
may be very different if control mosquitoes are infected by
an average of say two oocysts or 230 oocysts. The compu-
ter simulation supports this conclusion. The model used
assumes that the proportion of uninfected mosquitoes
can be predicted from the distribution of oocysts in con-
trol mosquitoes, the probability that each oocyst will beMalaria Journal 2007, 6:107 http://www.malariajournal.com/content/6/1/107
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killed is fixed by the feeding conditions and is independ-
ent of the oocyst distribution. The fit between the simu-
lated and actual data sets for P. vivax is important since the
input data on which this simulation is based contained
control feeds with a wide range of oocysts per mosquito.
Although the overall fit was good, for P. vivax this simple
model deviated from ideal in two ways. There were a
number of outliers at low proportions of mosquitoes
infected (Figure 7b). Examination of these individual data
points showed that they were derived from experimental
feeds where the estimated probability of survival had large
errors. For example, in Figure 7b, the data point (5.9, 64)
is from an experimental feed that resulted in a 1/19 mos-
quitoes being infected and this infected mosquito had 40
oocysts. The model also deviated from observed for feeds
where the test feeds had negligible transmission-blocking
activity (i.e., for experimental data with a high %
infected). At least part of this is due to an artifact intro-
duced to simplify the model: experimentally derived val-
ues of inhibition were used as the basis of the model. At
low antibody levels, random fluctuations in the number
of oocysts result in some samples with an apparent
enhancement of oocyst numbers or % of mosquitoes
infected. As the model did not allow an apparent
enhancement, (probability of survival must be <= 1.0),
this leads to a systematic error for those pairs of experi-
mental and simulated data at high infectivities and partic-
ularly where the actual number of infected mosquitoes is
greater than the average number in the control groups.
Conclusion
Notwithstanding the limits of such a simple model, the
results presented in this paper show that within the limits
of the MFA, the reduction in the oocyst density per mos-
quito can be predicted from the concentration of anti-P25
antibody and that this reduction is largely independent of
the species from which the antibody is derived, or from
the formulation and adjuvants used to generate the anti-
body. Furthermore, the proportion of mosquitoes that fail
to become infected can also be predicted from the distri-
bution of oocysts in control mosquitoes and from the %
reduction in the oocyst density in the presence of anti-
body. Since the rationale for developing MSTB vaccines is
to reduce the number of infected mosquitoes in the field,
there is now a theoretical basis for linking antibody pro-
duction in Phase 1 and Phase 2 vaccine trials to predicted
reduction in transmission. While this relationship will
have to be confirmed at each stage through the develop-
ment of a vaccine, the prospect that ELISA values can at
least in part replace cumbersome MFA as measure of
transmission-blocking activity will greatly facilitate future
trials of this and other mosquito stage vaccine candidates.
Moreover, it also establishes a benchmark for the anti-
body levels which must be achieved in order to attain a
defined level of transmission-blocking activity. These
studies thus provide strong support that transmission-
blocking activity for both P. falciparum and P. vivax para-
site antigens P25 is a direct and predictable function of
antibody concentration.
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